Finger Or Toe Endoprosthesis — Cost, Top Hospitals & Success Rates | MyMedicPlus

Finger and toe endoprosthesis (small joint arthroplasty) involves surgical replacement of diseased or damaged interphalangeal or metacarpophalangeal joints of the fingers, or metatarsophalangeal and interphalangeal joints of the toes, with an artificial implant. These tiny joint replacements are designed to restore pain-free movement, maintain finger and toe alignment, and preserve functional grip and gait mechanics. The development of modern small joint prostheses has evolved significantly since Swanson's silicone flexible implants in the 1960s, with contemporary designs including silicone spacers, pyrocarbon unconstrained implants, and metal-on-polyethylene total joint replacements.

The most commonly replaced finger joints are the proximal interphalangeal (PIP) joint — the middle knuckle — and the metacarpophalangeal (MCP) joint at the base of the finger. These joints are highly demanding biomechanically: the PIP joint undergoes complex flexion-extension and rotational forces during pinch and grip. For toes, the first metatarsophalangeal (MTP) joint is most frequently replaced, particularly in hallux rigidus (degenerative arthritis of the great toe joint) where conservative management fails to restore comfortable walking.

Patient selection, implant design choice, and surgical technique are critically important for outcomes in small joint arthroplasty. Hand surgeons and orthopaedic subspecialists with specific small joint arthroplasty training should perform these procedures. Pre-operative evaluation includes weight-bearing foot radiographs (for MTP arthroplasty), fluoroscopic assessment of joint dimensions, and assessment of soft tissue envelope and tendon integrity, all of which determine implant suitability.

Finger endoprosthesis is primarily indicated for end-stage inflammatory arthritis — particularly rheumatoid arthritis, which progressively destroys MCP and PIP joints causing ulnar deviation, boutonnière, and swan-neck deformities. Osteoarthritis of the PIP and DIP joints, post-traumatic arthritis following intra-articular fractures or dislocations, and avascular necrosis of the femoral head equivalent lesions in small joints are secondary indications. For the MCP joints, rheumatoid disease with significant joint destruction and loss of flexion is the classic indication.

For toes, first MTP arthroplasty addresses hallux rigidus (grade III-IV) — severe degenerative joint disease of the great toe causing pain on push-off and dorsiflexion limitation. Rheumatoid arthritis affecting the lesser MTP joints causing painful subluxation and digital deformity (hammer toes, claw toes) with significant joint destruction may be managed with small silicone or pyrocarbon implants. Avascular necrosis of the first metatarsal head is an uncommon indication.

Ideal candidates for finger joint arthroplasty are patients over 50 with moderate to severe rheumatoid or osteoarthritis-related joint destruction, significant pain limiting daily activities, and adequate bone stock to accommodate an implant. Inflammatory arthritis patients should have their systemic disease well controlled prior to surgery, as active synovitis and immunosuppression affect wound healing and infection risk. Patients with good soft tissue envelope, intact intrinsic musculature, and reasonable bone density are technically favoured candidates.

Contraindications include active joint or systemic infection, severe osteoporosis (insufficient bone stock for implant fixation), prior avascular bone changes that preclude implant seating, significant peripheral vascular disease limiting wound healing, and uncontrolled systemic inflammatory disease. Pyrocarbon implants for PIP joint replacement are contraindicated in patients with poor bone quality, active synovitis, or deformities requiring constrained designs. Patients who require high-impact digital use for occupational or recreational activities should be counselled that joint replacement limits such activities and that arthrodesis (fusion) may provide more reliable pain relief with greater durability.

Several implant designs are available for finger joint arthroplasty. Silicone flexible implants (Swanson-type) act as dynamic spacers rather than true joints — they provide stability and pain relief but do not recreate normal joint kinematics. They remain widely used for MCP joint replacement in rheumatoid arthritis due to predictable results and long-term follow-up data (20+ years). Pyrocarbon unconstrained implants (NeuFlex, Ascension) more closely approximate normal joint mechanics and are increasingly used for PIP joint replacement, particularly in younger, more active patients with OA.

For the first MTP joint, total joint replacement systems (bipolar hemi-arthroplasty or total arthroplasty) are available alongside silicone interposition arthroplasty. Hallux MTP arthrodesis (fusion in the optimal functional position) remains the gold standard for hallux rigidus and is often preferred over arthroplasty for its durability and predictability, particularly in younger patients. Surgical approaches vary: dorsal incision for finger MCP and PIP joints; dorsal or medial incision for first MTP; careful soft tissue balancing and collateral ligament reconstruction are important adjuncts at the time of implantation. Shared decision-making between patient and specialist, guided by current evidence-based clinical guidelines and the patient's individual anatomy, comorbidities, and treatment goals, is essential for selecting the most appropriate treatment modality. Pre-treatment specialist consultation, review of relevant investigations, and multidisciplinary input for complex presentations ensure the best possible outcomes.

MCP joint silicone arthroplasty for rheumatoid arthritis achieves significant pain relief in 85–90% of patients, with improvement in grip strength and functional arc of motion. Published series report average post-operative MCP flexion arcs of 45–55°, compared to often near-zero pre-operative in end-stage RA. Patient-reported outcomes on hand function questionnaires (DASH, PRWE) show clinically meaningful improvement at 1–2 years. Long-term 10-year follow-up data show implant survival (freedom from revision) of approximately 75–85% for silicone MCP implants.

Pyrocarbon PIP joint arthroplasty in carefully selected OA patients shows 70–80% good to excellent results at 5 years with preservation of 40–60° functional PIP flexion arc. First MTP arthroplasty for hallux rigidus achieves pain-free walking in 80–85% of patients at 2 years; arthroplasty preserves some range of motion compared to arthrodesis, which sacrifices motion for reliability. Overall, patients selecting small joint arthroplasty can expect marked pain reduction, improved daily function, and cosmetic improvement in joint alignment.

General complications of small joint arthroplasty include infection (1–3%), wound healing problems (more common in rheumatoid patients on immunosuppressants), nerve injury causing digital numbness or dysaesthesia (less than 1%), and complex regional pain syndrome (CRPS, approximately 0.5–2%). Implant-specific complications include silicone synovitis — a foreign body reaction to particulate debris from silicone implant fracture, occurring in 5–10% over 10 years — causing painful swelling and requiring implant removal and revision. Implant fracture rates for silicone MCP implants are up to 15% at 5 years but clinical symptoms from asymptomatic fracture are uncommon.

Pyrocarbon PIP implant complications include loosening, stiffness, and instability if soft tissue balancing is inadequate, with reported revision rates of 10–20% at 5–7 years. First MTP arthroplasty revision rates are higher than for hip or knee arthroplasty due to the smaller bone stock and greater mechanical demands per unit area during ambulation. Peri-implant fracture, implant subsidence, and metatarsalgia from altered weight distribution are known complications. Aseptic loosening requiring revision occurs in 5–15% of total MTP arthroplasties at 5 years.

Post-operative management after finger joint arthroplasty involves immobilisation in a customised dynamic splint for 4–6 weeks, followed by graded hand therapy for range of motion, grip strength, and fine motor skill restoration. Hand therapy is a critical determinant of functional outcome and typically involves 8–12 sessions. Weight bearing is gradually introduced after first MTP arthroplasty — toe-touch weight bearing for 2 weeks, then progressive full weight bearing in a stiff-soled shoe for 6 weeks, transitioning to normal footwear at 10–12 weeks.

Follow-up radiographs at 6 weeks, 3 months, and annually thereafter assess implant position and signs of loosening or wear. Rheumatoid patients on biologic therapy (TNF inhibitors, rituximab) require peri-operative management in coordination with their rheumatologist — typically holding biologics for 1–2 half-lives before surgery and resuming when wound healing is confirmed. Patients should be counselled that implant longevity is finite: a second revision operation may be required 10–20 years after the first, and the surgical options at revision (including arthrodesis) should be discussed pre-operatively.

Small joint arthroplasty in the US costs USD 5,000–12,000 per joint, including surgeon, anaesthesia, implant, and facility fees. Multiple joint replacements in the same surgical session (as often performed for rheumatoid MCP disease) increase total costs proportionally. UK NHS performs small joint arthroplasty for rheumatoid arthritis when conservative measures fail; private costs are GBP 3,000–7,000 per procedure.

Medical tourism for hand and foot arthroplasty is available at leading orthopaedic centres in India (USD 1,500–3,500 per joint), Thailand, and Turkey — representing 60–75% savings versus US prices. Patients considering overseas procedures should verify the availability of dedicated hand surgery specialists with small joint arthroplasty fellowship training, the range of implant systems available, and the provision of post-operative hand therapy, which is critical for outcome. Ongoing rheumatology follow-up and physiotherapy must continue on return home.

Arthrodesis (joint fusion) is the main surgical alternative to joint replacement for both finger and toe joints. For PIP and DIP finger joints, fusion is often preferred over arthroplasty as it provides more durable pain relief with no implant-related complications — at the cost of permanent loss of joint movement. For the first MTP joint, fusion (Lapidus or first MTP arthrodesis) remains the gold standard in most centres with superior long-term outcomes compared to arthroplasty, particularly in younger patients.

Conservative alternatives before surgery include intra-articular corticosteroid injections (2–3 per year maximum for small joints), hyaluronic acid injections for osteoarthritic joints, custom orthotics and toe splints, anti-inflammatory medication, and foot wear modification. Disease-modifying anti-rheumatic drugs (DMARDs) and biologics for rheumatoid arthritis can slow joint destruction and delay or avoid the need for surgical intervention if initiated early in the disease course.